In vivo effects of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible staphylococcus aureus strain showing an inoculum effect against cefazolin

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4276-4281

  Nannini, Esteban C ^a   Singh, Kavindra V ^b   Arias, Cesar A ^b   Murray, Barbara E ^b,c  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; DAPTOMYCIN; NAFCILLIN; NITROCEFIN; NOVOBIOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL LOAD; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DNA SEQUENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH TEMPERATURE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RAT; RELAPSE; TREATMENT DURATION;

EID: 84882298759     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00856-13     Document Type: Article

References (48)

1. Richmond MH. 1975. Immunological techniques for studying betalactamases. Methods Enzymol. 43:86-100.
2. Kernodle DS, McGraw PA, Stratton CW, Kaiser AB. 1990. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants. Antimicrob. Agents Chemother. 34:420-425.
3. Kernodle DS, Stratton CW, McMurray LW, Chipley JR, McGraw PA. 1989. Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles. J. Infect. Dis. 159:103-108.
4. Voladri RK, Kernodle DS. 1998. Characterization of a chromosomal gene encoding type B beta-lactamase in phage group II isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 42:3163-3168.
5. Zygmunt DJ, Stratton CW, Kernodle DS. 1992. Characterization of four beta-lactamases produced by Staphylococcus aureus. Antimicrob. Agents Chemother. 36:440-445.
6. Bryant RE, Alford RH. 1977. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 237:569-570.
7. Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, Fowler VG, Jr, Murray BE. 2009. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob. Agents Chemother. 53:3437-3441.
8. Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F. 1973. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J. Infect. Dis. 128(Suppl):S386-S389.
9. Fernandez-Guerrero ML, de Gorgolas M. 2005. Cefazolin therapy for Staphylococcus aureus bacteremia. Clin. Infect. Dis. 41:127.
10. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, Bisno AL, Ferrieri P, Shulman ST, Durack DT. 1995. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 274:1706-1713.
11. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434.
12. McHugh GL, Swartz MN. 1977. Elimination of plasmids from several bacterial species by novobiocin. Antimicrob. Agents Chemother. 12:423-426.
13. Shore AC, Brennan OM, Ehricht R, Monecke S, Schwarz S, Slickers P, Coleman DC. 2010. Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. Antimicrob. Agents Chemother. 54:4978-4984.
14. CLSI. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Murray BE, Singh KV, Ross RP, Heath JD, Dunny GM, Weinstock GM. 1993. Generation of restriction map of Enterococcus faecalis OG1 and investigation of growth requirements and regions encoding biosynthetic function. J. Bacteriol. 175:5216-5223.
16. Entenza JM, Hohl P, Heinze-Krauss I, Glauser MP, Moreillon P. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
17. Singh KV, Nallapareddy SR, Sillanpaa J, Murray BE. 2010. Importance of the collagen adhesin ace in pathogenesis and protection against Enterococcus faecalis experimental endocarditis. PLoS Pathog. 6:e1000716. doi: 10.1371/journal.ppat.1000716.
18. Xiong YQ, Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. 2005. Real-time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics in a rat Staphylococcus aureus endocarditis model. Antimicrob. Agents Chemother. 49:380-387.
19. Murillo O, Garrigos C, Pachon ME, Euba G, Verdaguer R, Cabellos C, Cabo J, Gudiol F, Ariza J. 2009. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4252-4257.
20. Catherall EJ, Gillon V, Hurn S, Irwin R, Mizen L. 1992. Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats. Antimicrob. Agents Chemother. 36:458-462.
21. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718.
22. Wold JS. 1977. Rapid analysis of cefazolin in serum by high-pressure liquid chromatography. Antimicrob. Agents Chemother. 11:105-109.
23. Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O. 2009. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin. Pharmacol. 9:1.
24. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent end points. Am. J. Hyg. 27:493-497.
25. Rowland SJ, Dyke KG. 1989. Characterization of the staphylococcal betalactamase transposon Tn552. EMBO J. 8:2761-2773.
26. Goldman PL, Petersdorf RG. 1980. Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus. J. Infect. Dis. 141:331-337.
27. Carrizosa J, Kobasa WD, Snepar R, Kaye KM, Kaye D. 1982. Cefazolin versus cephalothin in beta-lactamase-producing Staphylococcus aureus endocarditis in a rabbit experimental model. J. Antimicrob. Chemother. 9:387-393.
28. Chapman SW, Steigbigel RT. 1983. Staphylococcal beta-lactamase and efficacy of beta-lactam antibiotics: in vitro and in vivo evaluation. J. Infect. Dis. 147:1078-1089.
29. Kozatani J, Okui M, Matsubara T, Nishida M. 1972. Cefazolin, a new semisynthetic cephalosporin antibiotic. VI. Excretion and metabolism of cefazolin-14 C in rats after intramuscular administration. J. Antibiot. 25: 86-93.
30. Lee FH, Pfeffer M, Van Harken DR, Smyth RD, Hottendorf GH. 1980. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob. Agents Chemother. 17: 188-192.
31. Patel R, Piper KE, Rouse MS, Steckelberg JM. 2000. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob. Agents Chemother. 44:3438-3440.
32. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. 1992. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36:2709-2714.
33. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 48:4665-4672.
34. Figueroa DA, Mangini E, Amodio-Groton M, Vardianos B, Melchert A, Fana C, Wehbeh W, Urban CM, Segal-Maurer S. 2009. Safety of highdose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49:177-180.
35. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
36. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. 2010. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:610-613.
37. Marco F, de la Maria CG, Armero Y, Amat E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jimenez de Anta MT, Miro JM. 2008. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2538-2543.
38. Wang PZ, Novick RP. 1987. Nucleotide sequence and expression of the beta-lactamase gene from Staphylococcus aureus plasmid pI258 in Escherichia coli, Bacillus subtilis, and Staphylococcus aureus. J. Bacteriol. 169: 1763-1766.
39. Chan PT. 1986. Nucleotide sequence of the Staphylococcus aureus PC1 beta-lactamase gene. Nucleic Acids Res. 14:5940.
40. Murphy E, Novick RP. 1979. Physical mapping of Staphylococcus aureus penicillinase plasmid pI524: characterization of an invertible region. Mol. Gen. Genet. 175:19-30.
41. Rice LB, Marshall SH. 1992. Evidence of incorporation of the chromosomal beta-lactamase gene of Enterococcus faecalis CH19 into a transposon derived from staphylococci. Antimicrob. Agents Chemother. 36:1843-1846.
42. Murray BE, Mederski-Samaroj B. 1983. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J. Clin. Invest. 72:1168-1171.
43. Cohen S, Sweeney HM. 1968. Constitutive penicillinase formation in Staphylococcus aureus owing to a mutation unlinked to the penicillinase plasmid. J. Bacteriol. 95:1368-1374.
44. East AK, Curnock SP, Dyke KG. 1990. Change of a single amino acid in the leader peptide of a staphylococcal beta-lactamase prevents the appearance of the enzyme in the medium. FEMS Microbiol. Lett. 57:249-254.
45. Lee S, Choe PG, Song KH, Park SW, Kim HB, Kim NJ, Kim EC, Park WB, Oh MD. 2011. Is cefazolin inferior to nafcillin for treatment of methicillin- susceptible Staphylococcus aureus bacteremia? Antimicrob. Agents Chemother. 55:5122-5126.
46. Paul M, Zemer-Wassercug N, Talker O, Lishtzinsky Y, Lev B, Samra Z, Leibovici L, Bishara J. 2011. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin. Microbiol. Infect. 17:1581-1586.
47. Livorsi DJ, Crispell E, Satola SW, Burd EM, Jerris R, Wang YF, Farley MM. 2012. Prevalence of blaZ gene types and the inoculum effect with cefazolin among bloodstream isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 56:4474-4477.
48. Rincon S, Reyes J, Carvajal LP, Rojas N, Cortes F, Panesso D, Guzman M, Zurita J, Adachi JA, Murray BE, Nannini EC, Arias CA. 21 June 2013, posting date. Cefazolin high-inoculum effect in methicillinsusceptible Staphylococcus aureus from South American hospitals. J. Antimicrob. Chemother. [Epub ahead of print.] doi:10.1093/jac/dkt254.